{"DataElement":{"publicId":"6117719","version":"1","preferredName":"Breast Carcinoma Estrogen Receptor Status","preferredDefinition":"The estrogen receptor status of a primary breast tumor or metastases.","longName":"BRCA_ER_STAT","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6117712","version":"1","preferredName":"Breast Carcinoma Estrogen Receptor Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","longName":"2475941v1.0:2534137v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2534137","version":"1","preferredName":"Estrogen Receptor Status","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and","longName":"C16150","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status","conceptCode":"C16150","definition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21202FE6-7AC7-362E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D63326-9C1D-732A-E053-F662850A452C","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6117714","version":"1","preferredName":"Estrogen Receptor Status","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease._A condition or state at a particular time.","longName":"6117714v1.0","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"Estrogen Receptor Status 0","ValueMeaning":{"publicId":"6117715","version":"1","preferredName":"Estrogen Receptor Status 0","longName":"6117715","preferredDefinition":"An immunohistochemical result of 0 for estrogen receptor expression that is considered negative for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status 0","conceptCode":"C147852","definition":"An immunohistochemical result of 0 for estrogen receptor expression that is considered negative for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AA7C-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DEDE5A-AA95-1E0B-E053-F662850A4C23","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"3+","valueDescription":"Estrogen Receptor Status 3+","ValueMeaning":{"publicId":"6117716","version":"1","preferredName":"Estrogen Receptor Status 3+","longName":"6117716","preferredDefinition":"An immunohistochemical result of 3 for estrogen receptor expression that is considered positive for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status 3+","conceptCode":"C147855","definition":"An immunohistochemical result of 3 for estrogen receptor expression that is considered positive for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AAA1-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DEDE5A-AABA-1E0B-E053-F662850A4C23","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"2+","valueDescription":"Estrogen Receptor Status 2+","ValueMeaning":{"publicId":"6117717","version":"1","preferredName":"Estrogen Receptor Status 2+","longName":"6117717","preferredDefinition":"An immunohistochemical result of 2 for estrogen receptor expression that is considered intermediate for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status 2+","conceptCode":"C147854","definition":"An immunohistochemical result of 2 for estrogen receptor expression that is considered intermediate for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AAC6-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DEDE5A-AADF-1E0B-E053-F662850A4C23","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"1+","valueDescription":"Estrogen Receptor Status 1+","ValueMeaning":{"publicId":"6117718","version":"1","preferredName":"Estrogen Receptor Status 1+","longName":"6117718","preferredDefinition":"An immunohistochemical result of 1 for estrogen receptor expression that is considered weak for expression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status 1+","conceptCode":"C147853","definition":"An immunohistochemical result of 1 for estrogen receptor expression that is considered weak for expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AAEB-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66DEDE5A-AB04-1E0B-E053-F662850A4C23","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682944","version":"1","preferredName":"Unknown","longName":"5682944","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AE5-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66EC1827-B7C1-21A7-E053-F662850AEAAE","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6117713","version":"1","preferredName":"Estrogen Receptor Status Status","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.:A condition or state at a particular time.","longName":"C16150:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status","conceptCode":"C16150","definition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AA50-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66DEDE5A-AA61-1E0B-E053-F662850A4C23","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"BRCA_ER_STAT","type":"USED_BY","context":"CCTG"}],"ReferenceDocuments":[{"name":"Estrogen receptor (ER) status","type":"Preferred Question Text","description":"Estrogen receptor (ER) status","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66D7C518-F8A3-65E5-E053-F662850A5C83","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-08","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 3/8/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}